KHK and metabolic dysfunction-associated steatohepatitis: Given the conflicting outcomes resulting from KHK deficiency in the liver and gut, new therapies for fructose‐driven NASH should focus on preventing inflammation, endoplasmic reticulum stress, and gut barrier deterioration, among others.253